<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093336</url>
  </required_header>
  <id_info>
    <org_study_id>2018-DFSC-002</org_study_id>
    <nct_id>NCT04093336</nct_id>
  </id_info>
  <brief_title>Effect of Different Transplantation Time for Mesenchymal Stem Cells(MSCs) of Cerebral Infarction Patients</brief_title>
  <official_title>Effect of Different Transplantation Time for Human Umbilical Cord Mesenchymal Stem Cells(MSCs) on Prognosis of Acute Cerebral Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai East Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai East Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo controlled, randomized, double blinded study including Phase 1 and Phase 2.
      Phase I study is a safety assessment and Phase 2 study is incline to assess effectiveness of
      MSCs. Potential subjects must be screened and consented before enrolled.

      The primary objective of this study is to determine the effects of different time points for
      intravenous infusion of allogeneic human umbilical cord mesenchymal stem cells (HucMSCs or
      MSCs used in the following section) for patients with acute ischemic stroke. Eligible
      patients will receive a single dose of MSCs or placebo within 12 hours or 5-7days after
      stroke. Patients will be followed for 2 years post infusion for safety and efficacy (change
      in neurological symptoms and quality of life). Assessments will occur during transplantation
      and at 3,7, 14 days and1,3, 6, 12, 18 and 24 months after infusions of stem cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Phase 1 study, the eligible patients with acute cerebral infarction 5-7 days after onset
      will be randomized to MSCs group or control group and receive intravenous MSCs 2 x 10^6/kg or
      placebo as a single dose, respectively. Each group will enroll 10 patients and patients will
      be followed for 2 years to observe the adverse events and evaluate the safety of MSCs for
      acute ischemic stroke patients.

      The safety and preliminary effectiveness of MSCs in the treatment of acute cerebral
      infarction will be summarized after all patients of Phase 1 study were followed for 3 months
      post infusion, and the report will be submit to the academic committee and the ethics
      committee to evaluate before approval to begin the Phase 2 study.

      In Phase 2 study, 100 patients with acute infarction within 12 hours after onset or 5-7 days
      after onset will be enrolled and randomized to MSCs group or control group. Patients will
      have baseline laboratory examinations and cerebral image (MRI or CTP). Enrolled patients will
      receive intravenous infusion of 2*10^6/kg MSCs or placebo for a single dose and follow for 24
      months to assess the adverse events, neurological functional recovery and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 13, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo controlled, randomized, double blinded</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>24 months post transplantation</time_frame>
    <description>include tumorigenesis, death, pulmonary embolism, allergy, newly cerebrovascular events and other adverse events to evaluate the safety of MSCs for acute ischemic stroke patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the National Institutes of Health Stroke Scale (NIHSS) of 3 months</measure>
    <time_frame>3 months post transplantation</time_frame>
    <description>The NIHSS neurologic examination includes 15 individual elements that measure motor and sensory function, language and speech production, vision, level of consciousness and attention, and neglect. The scores of each element are summed (range from 0 to 42) to evaluate the severity of neurological deficits. The more higher score means the more severe neurological dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Barthel index (BI) of 3 months</measure>
    <time_frame>3 months post transplantation</time_frame>
    <description>The BI (range from 0 to 100) are used to assess the difference of activities of daily living between two groups. the score ≤40 means severe dependence， score 41~60 means moderate dependence, score 61~99 means mild dependence and score 100 means independence.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Infarction, Middle Cerebral Artery</condition>
  <condition>Infarction, Anterior Cerebral Artery</condition>
  <condition>Cerebral Infarction</condition>
  <condition>Stroke, Ischemic</condition>
  <condition>Acute Stroke</condition>
  <arm_group>
    <arm_group_label>MSCs group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The people in this group will receive intravenous MSCs 2 x 10^6/kg as a single dose and standardized treatment of acute ischemic stroke.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The people in this group will receive placebo and standardized treatment of acute ischemic stroke.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human umbilical cord mesenchymal stem cells</intervention_name>
    <description>The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.</description>
    <arm_group_label>MSCs group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standardized treatment</intervention_name>
    <description>standardized treatment</description>
    <arm_group_label>MSCs group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute ischemic stroke;

          2. Age 18~80y;

          3. 4≤NIHSS score≤18（including limb score≥2）and modified Rankin scale 0-1 before this
             cerebral ischemic stroke;

          4. patients and their families understand and will cooperate within the whole process of
             study, and sign informed consent;

          5. any of following items：①cerebral infarction in the internal carotid artery territory
             confirmed by cerebral CT perfusion &lt; 12 hours after onset or ②cerebral infarction in
             the internal carotid artery territory confirmed by cerebral MR image 5 to 7 days after
             onset.

        Exclusion Criteria:

          1. cardiogenic embolism by TOAST classification;

          2. accompanied by hematological disease, severe infection, liver dysfunction (ALT&gt;3*ULN),
             kidney dysfunction (Scr &gt;2*ULN), cardiac dysfunction (NYHA grade III or IV);

          3. Disturbance of consciousness, mental illness, cognitive impairment and other diseases
             that may affect informed consent and evaluation of study.

          4. Malignancy history or found to associate cancer after this stroke

          5. Pregnant or lactating women, or women have fertility requirements within 2 years;

          6. Accompanied by immunodeficiency diseases or autoimmune diseases;

          7. Life expectancy is less than 2 years;

          8. Participated in other clinical trial within 6 months;

          9. Patients received Chinese traditional medicine after onset of this stroke;

         10. Patients with allergic predisposition;

         11. Mental implantation or other reasons cannot tolerate magnetic resonance imaging;

         12. Cannot follow up regularly or unwilling to sign informed consent;

         13. Other situations not suitable for enrollment judged by the researchers;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Li, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gang Li</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cao W, Li P. Effectiveness and Safety of Autologous Bone Marrow Stromal Cells Transplantation After Ischemic Stroke: A Meta-Analysis. Med Sci Monit. 2015 Jul 28;21:2190-5. doi: 10.12659/MSM.895081.</citation>
    <PMID>26215395</PMID>
  </reference>
  <results_reference>
    <citation>GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.</citation>
    <PMID>25530442</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao Y, Yao Z, D'Souza W, Zhu C, Chun H, Zhuoga C, Zhang Q, Hu X, Zhou D. An epidemiological survey of stroke in Lhasa, Tibet, China. Stroke. 2010 Dec;41(12):2739-43. doi: 10.1161/STROKEAHA.110.586669. Epub 2010 Oct 21.</citation>
    <PMID>20966420</PMID>
  </results_reference>
  <results_reference>
    <citation>Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008 May 10;371(9624):1612-23. doi: 10.1016/S0140-6736(08)60694-7. Review.</citation>
    <PMID>18468545</PMID>
  </results_reference>
  <results_reference>
    <citation>Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Mar;44(3):870-947. doi: 10.1161/STR.0b013e318284056a. Epub 2013 Jan 31.</citation>
    <PMID>23370205</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ, Wu TY, Brooks M, Simpson MA, Miteff F, Levi CR, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Priglinger M, Ang T, Scroop R, Barber PA, McGuinness B, Wijeratne T, Phan TG, Chong W, Chandra RV, Bladin CF, Badve M, Rice H, de Villiers L, Ma H, Desmond PM, Donnan GA, Davis SM; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 Mar 12;372(11):1009-18. doi: 10.1056/NEJMoa1414792. Epub 2015 Feb 11.</citation>
    <PMID>25671797</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009 Jul 2;5(1):54-63. doi: 10.1016/j.stem.2009.05.003.</citation>
    <PMID>19570514</PMID>
  </results_reference>
  <results_reference>
    <citation>Crigler L, Robey RC, Asawachaicharn A, Gaupp D, Phinney DG. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol. 2006 Mar;198(1):54-64. Epub 2005 Dec 5.</citation>
    <PMID>16336965</PMID>
  </results_reference>
  <results_reference>
    <citation>Ikeda N, Nonoguchi N, Zhao MZ, Watanabe T, Kajimoto Y, Furutama D, Kimura F, Dezawa M, Coffin RS, Otsuki Y, Kuroiwa T, Miyatake S. Bone marrow stromal cells that enhanced fibroblast growth factor-2 secretion by herpes simplex virus vector improve neurological outcome after transient focal cerebral ischemia in rats. Stroke. 2005 Dec;36(12):2725-30. Epub 2005 Nov 10.</citation>
    <PMID>16282547</PMID>
  </results_reference>
  <results_reference>
    <citation>Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y, Shi Y. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med. 2012 Jan;1(1):51-8. doi: 10.5966/sctm.2011-0019. Epub 2011 Dec 7. Review.</citation>
    <PMID>23197640</PMID>
  </results_reference>
  <results_reference>
    <citation>Vu Q, Xie K, Eckert M, Zhao W, Cramer SC. Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. Neurology. 2014 Apr 8;82(14):1277-86. doi: 10.1212/WNL.0000000000000278. Epub 2014 Mar 7.</citation>
    <PMID>24610327</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute cerebral infarction ,Mesenchymal Stem Cells,prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
    <mesh_term>Infarction, Anterior Cerebral Artery</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

